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ﬁed the study population into groups by their oral hypoglycemic agents, and further 
analyzed the hazard ratio of myocardial infarction (MI) in different add-on medication 
and the survival of cardiovascular diseases between add-on TZDs group and non-TZD 
group. NMB regression model was used to estimate the cost-effectiveness difference 
on patients who used TZDs versus non-TZD users. RESULTS: The Cox proportional 
hazard model analysis demonstrated that sulfonylurea +rosiglitazone group had a 
higher risk of hospitalization for cardiovascular diseases comparing to add-on met-
formin group (HR 1.48, 95% CI: 1.21–1.80); As to the cost-effectiveness analysis: 1) 
Comparing to sulfonylurea+metformin group, the average annual medication cost 
(AAMC) per capita of sulfonylurea+rosiglitazone group increased NT$12,944, but the 
average days for hospitalization decreased 0.12 day; while the AAMC of sulfonylurea 
+pioglitazone group increased NT$10,329, but the average days for hospitalization 
decreased 0.22 day. 2) Comparing to metformin+sulfonylurea group, the AAMC of 
metformin+rosiglitazone group increased NT$11,486 dollars, but the average day for 
hospitalization decreased 0.09 day; while metformin+rosiglitazone group increased 
NT$11267, but the average days for hospitalization decreased 0.18 day. CONCLU-
SIONS: Our results demonstrated that sulfonylurea + rosiglitazone group had a higher 
risk of hospitalization for cardiovascular diseases versus metformin group with TZD 
add-on treatment (HR 1.48, 95% CI: 1.21–1.80), and per capita AAMC was higher 
(NT$12944 increment) which was not justiﬁed in the decrease of 0.12 hospitalization 
days 0.12. As for other metformin add-on groups, the increased medication cost was 
also not justiﬁed.
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OBJECTIVES: The primary purpose of this study is to estimate the cost efﬁciency of 
the diabetes medications in Medicare in the year 2005 and the year 2006 to investigate 
the impact of Medicare, Part D. METHODS: In this study, several data sets from the 
Medical Expenditure Panel Survey are used as collected by the Agency for Healthcare 
Research and Quality. The data sets provide information on the prescribed drug, 
demography, ofﬁce-based visits, outpatients and inpatients for the years 2005 and 
2006.The analysis is based on the Medicare payments for anti-diabetic drugs, without 
considering the drug forms and cost-efﬁciency as measured by the Medicare payment 
amounts for ofﬁce-based visits, inpatients or outpatients. Statistics methods used 
include One-Way Frequencies, Summary Statistics, Box and Whisker Plots, Linear 
Multiple Regression and Spearman’s rank correlation. SAS SQL and some SAS func-
tions such as the MDY function and 0–1 indicator functions are utilized to preprocess 
the data. RESULTS: Results demonstrate that metformin users have fewer physician 
visits, lab tests and shorter length of stay in the hospital and it has a negative relation-
ship with the former two factors. Insulin, metformin and its combination with glybu-
ride are signiﬁcant to predict the frequencies of doctor ofﬁce visits, lab tests and length 
of stay. From the year 2005 to the year 2006, insulin and metformin users reduce 
their frequencies of physician visits and lab tests as well as days in the hospital. 
CONCLUSIONS: Among the diabetes medications in Medicare, metformin is the most 
cost-effective drug due to the fewest Medicare expenditures for ofﬁce-based visits, 
inpatients and outpatients with spending one dollar on the drug. In 2006, with Medi-
care part D, metformin becomes more efﬁcient, while insulin becomes more effective 
at the cost of an increased price .Therefore, it is recommended to prescribe metformin 
for the Medicare diabetic beneﬁciaries.
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OBJECTIVES: The NICE study was a ﬁve-year, open-label, randomized controlled 
trial that compared cardiovascular outcomes in Japanese type 2 diabetes patients 
intensively treated with human insulin (HI) or insulin aspart (IAsp). Using data from 
the NICE study, the cost-effectiveness of IAsp versus HI was evaluated from the 
perspective of a third-party health care payer over a ten-year time horizon (ﬁve years 
within-trial observation and ﬁve years post-trial extrapolation). METHODS: A dis-
crete event simulation model was developed in Microsoft Excel® to assess the within-
trial cost-effectiveness and make longer-term clinical projections in patients treated 
with regular human insulin or insulin aspart. Life expectancy, quality-adjusted life 
expectancy, cardiovascular event rates and costs were evaluated over a ten-year time 
horizon. Event costs were calculated from hospital receipt data supplied by the Japa-
nese Medical Data Center. Annual insulin costs were obtained from the NICE study. 
Other pharmacy costs were assumed to be the same in both treatment arms and were 
not captured in the analysis. All costs were expressed in 2008 Japanese Yen (JPY) and 
future costs and clinical beneﬁts were discounted at 3% annually. Sensitivity analyses 
were performed. RESULTS: Compared with HI, IAsp was dominant (life- and cost-
saving) over a ten-year time horizon. IAsp was associated with an improvement in 
discounted life expectancy of 0.056 years and an improvement of 0.085 quality-
adjusted life years (QALYs) versus HI. Insulin aspart was projected to save an average 
of JPY 290,719 per patient. As in the exclusively in-trial analysis, pharmacy costs were 
found to be higher (difference JPY 129,408), but were again more than offset by cost 
savings resulting from a reduced incidence of cardiovascular complications, a differ-
ence of JPY -420,126. CONCLUSIONS: In a Japanese type 2 diabetes population, 
prescribing rapid-acting insulin aspart signiﬁcantly reduced cardiovascular complica-
tions, resulting in increased quality of life and decreased costs compared with human 
insulin.
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OBJECTIVES: To estimate the economic and health consequences of the use of DPP4 
plus metformin in the treatment of patients with type 2 diabetes in Mexico METHODS: 
A cost-effectiveness analysis was done using a discrete event model to simulate the 
behavior of a hypothetic population with 40 years follow-up, to evaluate the number 
of complications (ischemic heart disease, myocardial infarction, congestive heart 
failure, stroke, amputation, retinopathy and ESRD), their costs and quality-adjusted 
life years (QALY’s); and the expected cost with the use of metformin+DPP4 (MDPP4), 
metformin+sulfonylureas (MSU), metformin+thiazolidinediones (MTZ) and metfor-
min (MF). The demographic and clinical background of the patients used in the model 
was obtained based on expert panel opinions (11 physicians). A systematic literature 
review was performed to get information on effectiveness (reduction in HbA1c level 
and related complications risk as reported in the UKPDS) and quality of life. Utiliza-
tion of health care resources was collected from clinical ﬁles (n = 182) at Hospital 
General Zona n° 8 of the Mexican Social Security Institute. Private costs of complica-
tion treatments were obtained from institutional sources applying a conversion ratio 
of 2.46 times as referred in the literature. Drug prices as based on private reference 
prices (ﬁxed by the regulatory authorities). All costs are expressed in 2009 US$. 
Probabilistic sensitivity analysis was performed (1000 Monte Carlo iterations) and 
acceptability curves were constructed. Both cost and QALY’s were discounted at 5% 
RESULTS: The expected treatment cost and QALY’s for MF is $250,213.26 and 
12.97 respectively; MSU $255,910.09 and 13.26; MTZ $255,177.26 and 13.27; 
MDPP4 $245,055.52 and 13.41. The probability of being cost-effective at a threshold 
of $30,621.30 (equivalent to 3 times the Mexican GDP per-capita) with MSU is 
0.543 CI95%(0.512–0.574); MTZ 0.593 CI95%(0.563–0.623); and MDPP4 
0.867 CI95%(0.846–0.888) CONCLUSIONS: The scheme based on metformin+DPP4 
presents the best cost effectiveness ratio against metformin+sulfonylureas or 
metformin+thiazolidinediones.
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OBJECTIVES: Diabetic Peripheral Neuropathic Pain (DPNP) is a chronic neuropathic 
condition that signiﬁcantly affects both health-related quality of life and functional 
status, causing depression and disabilities, increased health care utilization and high 
costs. We aimed to perform an economic evaluation of three recommended ﬁrst-line 
medications for DPNP. METHODS: The analysis was conducted using a three-month 
decision model, which compares duloxetine 60mg once daily (DUL), gabapentin 
600mg 3-times daily (GAB) and pregabalin 150mg twice daily (PRE) for patients with 
DPNP and moderate to severe pain, under the perspective of public health care system 
in Mexico. Efﬁcacy rates were gathered from published literature. Adherence (based 
in number of daily doses needed) and adverse effects (AE) rates were incorporated 
into the model. Direct medical costs included drug acquisition and additional medical 
consultation due to lack of efﬁcacy (poor pain relief) or intolerable AE. Unit costs 
were taken from local public tariffs. All costs were calculated in 2009 Mexican Pesos 
(MXP) and then expressed in USD. Proportion of patients with Good Pain Relief 
(GPR) and expected quality-adjusted life years (QALY) by patient was assessed. 
RESULTS: Branded GAB and PRE were both dominated by generic GAB and DUL. 
Compared to branded GAB and PRE, DUL leads to savings of 98 and 129 USD per 
patient, respectively. The incremental cost per QALY gained with DUL used instead 
of generic GAB is 8821 USD. This amount is similar to the estimated gross domestic 
product per capita in Mexico during 2008 year. DUL was cost-effective compared to 
generic GAB in about 83% of the samples during a second-order Monte Carlo simula-
tion. CONCLUSIONS: DUL had lower costs and better health outcomes when com-
pared to both branded GAB and PRE. According to the recommendations stated by 
the World Health Organization, DUL can be seen as a cost-effective intervention 
compared to generic GAB.
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OBJECTIVES: To compare the treatment costs in China of 2 basal insulin analogues, 
glargine and determir, when used in combination with oral antidiabetic drugs(basal 
supported oral therapy) in insulin naïve type 2 diabetes patients. METHODS: The 
